

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: GP2/22 - Detection of Monoclonal Components

Deadline: 23.09.2022

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

Test

Sample	Group	N	Result	N _{rel}	
(246) Gammopathies (typisation)					
A	(12) Beckman Coulter	>>> 1	IgA-kappa	1,1 %	
	(34) Sebia	>>> 61	IgA-kappa	65 %	
		>>> 3	IgA-kappa; kappa-free	3,2 %	
	(100) Helena	>>> 1	IgA-kappa	1,1 %	
	(213) Interlab Srl	>>> 26	IgA-kappa	28 %	
			IgA-kappa; IgG-kappa	1,1 %	
		>>> 1	IgA-kappa; kappa-free	1,1 %	
	----- Total per sample: n = 94 -----		Success: 99 %		
	B	(12) Beckman Coulter	>>> 1	IgG-lambda; lambda-free	1,1 %
		(34) Sebia		3 Not specified	3,2 %
			4 IgG-lambda; lambda	4,3 %	
		>>> 3	IgG-lambda; lambda; lambda-free	3,2 %	
		>>> 29	IgG-lambda; lambda-free	31 %	
			2 lambda	2,1 %	
		>>> 10	lambda; lambda-free	11 %	
		>>> 13	lambda-free	14 %	
(100) Helena		>>> 1	IgG-lambda; lambda-free	1,1 %	
(213) Interlab Srl			7 Not specified	7,4 %	
			1 IgG-lambda	1,1 %	
		>>> 1	IgG-lambda; lambda; lambda-free	1,1 %	
		>>> 5	IgG-lambda; lambda-free	5,3 %	
			3 lambda	3,2 %	
		>>> 3	lambda; lambda-free	3,2 %	
		>>> 8	lambda-free	8,5 %	
----- Total per sample: n = 94 -----		Success: 79 %			
Total success: 79 %					

st_kl

End of report

Printed: 07.10.2022